Testing MCLA-129 plus ensartinib for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new two-drug combination (MCLA-129 and ensartinib) for people with advanced solid tumors that have a specific genetic change called MET amplification or overexpression. The goal is to see if this combo can shrink tumors or stop them from growing when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have an advanced solid tumor (like lung, head and neck, or stomach cancer) that cannot be cured with standard treatments.
- Your tumor has a MET gene change, confirmed by a special lab test.
- You've had prior cancer treatments that stopped working or caused too many side effects.
- You are well enough to be up and about (ECOG score 0 or 1) and expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This study tests a new drug, MCLA-129, for people with advanced non-small cell lung cancer that has specific gene changes (EGFR and MET) and has stopped responding to standard treatments. The drug targets these changes to possibly slow or shrink the cancer.
This trial tests a targeted therapy pill called ensartinib for people with advanced solid tumors (other than lung cancer) that have an ALK or MET gene change. The drug works by blocking signals that help these cancers grow, and the study aims to see how well it works and if it's safe.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug combination (MCLA-129 and befotertinib) for people with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to see if the combination can shrink tumors or slow their growth, especially after other treatments have stopped working.
Hear when a new Solid Advanced Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.